At the news
? NEUTRALIMPACT 2/10 SC 13G/A filed Nov 5, 2026 at 13:16 ET
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 970,920 shares of Edgewise Therapeutics common stock as of September 30, 2026, representing 0.9% of shares outstanding. This is a routine passive stake update filed one day after Edgewise reported Q3 results that included a large one-time gain from the sale of sevasemten. The stake is unchanged from the prior filing, and the filing carries no directional signal.
- FMR LLC reported beneficial ownership of 970,920 shares of Edgewise Therapeutics common stock as of September 30, 2026
- The stake represents 0.9% of shares outstanding
- This is an amendment to a prior Schedule 13G filed August 6, 2026
- The filing was made under Rule 13d-1(b) indicating passive investment intent
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access